Table 1 Baseline characteristics of the study population
|  | Normal TyG index (≤ 9.51) | Elevated TyG index (> 9.51) | P-value |
|---|---|---|---|
n = 7672 | n = 1190 | ||
Age (years) | 61.4 ± 10.0 | 59.0 ± 9.8 |  < 0.001 |
Male | 6227 (81.2) | 838 (70.4) |  < 0.001 |
BMI (kg/m2) | 25.8 ± 3.1 | 26.3 ± 2.9 |  < 0.001 |
Family history of CAD | 2147 (28.0) | 400 (33.6) |  < 0.001 |
Previous myocardial infarction | 2772 (36.1) | 381 (32.0) | 0.006 |
Previous stroke | 768 (10.0) | 113 (9.5) | 0.617 |
Hypertension | 5157 (67.2) | 835 (70.2) | 0.047 |
Diabetes | 2315 (30.2) | 779 (65.5) |  < 0.001 |
Hyperlipidaemia | 4142 (54.0) | 815 (68.5) |  < 0.001 |
COPD | 93 (1.2) | 7 (0.6) | 0.080 |
PAD | 590 (7.7) | 99 (8.3) | 0.487 |
CKD | 56 (0.7) | 17 (1.4) | 0.021 |
Current/former smoker | 4306 (56.1) | 629 (52.9) | 0.037 |
Clinical presentation | |||
 SAP | 3070 (40.0) | 430 (36.1) | 0.012 |
 ACS | 4602 (60.0) | 760 (63.9) | 0.012 |
 LVEF (%) | 58.5 ± 9.3 | 58.3 ± 9.4 | 0.474 |
 CCr (mL/min) | 84.8 ± 26.5 | 89.8 ± 28.7 | < 0.001 |
 TyG index | 8.76 ± 0.39 | 9.92 ± 0.42 | < 0.001 |
 Left main involvement | 1827 (23.8) | 236 (19.8) | 0.003 |
SYNTAX score | |||
 ≤ 22 | 3027 (39.5) | 497 (41.8) | 0.317 |
 23–32 | 2871 (37.4) | 429 (36.1) | |
 ≥ 33 | 1774 (23.1) | 264 (22.2) | |
Treatment strategy | |||
 CABG | 2338 (30.5) | 338 (28.4) | 0.347 |
 PCI | 3269 (42.6) | 520 (43.7) | |
 MT | 2065 (26.9) | 332 (27.9) | |
Medication at discharge | |||
 Aspirin | 7327 (95.5) | 1149 (96.6) | 0.115 |
 Clopidogrel | 3985 (51.9) | 645 (54.2) | 0.155 |
 ACEI | 2796 (36.4) | 484 (40.7) | 0.005 |
 ARB | 1151 (15.0) | 196 (16.5) | 0.204 |
 Beta-blocker | 6713 (87.5) | 1075 (90.3) | 0.006 |
 CCB | 2764 (36.0) | 432 (36.3) | 0.879 |
 Statin | 5110 (66.6) | 815 (68.5) | 0.211 |